Research programme: gamma secretase inhibitors - Merck

Drug Profile

Research programme: gamma secretase inhibitors - Merck

Alternative Names: MRK-003; MRK-560

Latest Information Update: 06 Sep 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck & Co
  • Class Benzodiazepines; Small molecules; Sulfonamides; Sulfones
  • Mechanism of Action Amyloid precursor protein secretase inhibitors; Notch signalling pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Alzheimer's disease; Cancer

Most Recent Events

  • 16 Apr 2008 Pharmacodynamics and adverse events data from a preclinical trial in Cancer presented at the 99th Annual Meeting of the American Association for Cancer Research (AACR-2008)
  • 16 Apr 2008 Preclinical trials in Cancer in USA (PO)
  • 06 Sep 2004 Preclinical trials in Alzheimer's disease in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top